Loading..
  • Oasmia logo
  • Oasmia logo
  • About Us
  • Our Science
  • Corporate Governance
  • Investors
  • Media
  • Contact
  • About Us
    • Purpose, Vision & Mission
    • CEO corner
    • Organisation
      • Management
      • Board of Directors
    • Collaborations and partners
    • Career
      • Vacant positions
    • Sustainability / Corporate Responsibility
  • Our Science
    • XR-17 Technology Platform
      • Benefits
      • Therapeutic focus
      • IP protection
    • Commercialized products
      • Apealea
    • Project Portfolio
      • Docetaxel Micellar
      • XR-19
    • Animal Health
    • Research and development
  • Corporate Governance
    • Governance reports
    • General Meeting
    • Management
    • Board of Directors
    • Nomination Committee
    • Remuneration
    • Auditor
    • Code of Conduct
    • Articles of Association
    • Documents
  • Investors
    • Investment case
    • The Share
    • Ownership Structure
    • Financial Reports and Presentations
    • Analyst coverage
    • Prospectuses
    • Archive US listing
      • SEC Filings
      • Info regarding delisting of ADS from NASDAQ US
    • Press releases
    • Financial calendar
    • Subscribe
    • Contact
  • Media
    • Press releases
    • Presentations
    • Events
    • Subscribe
    • Contact
  • Contact
September 25, 2018

Annual General Meeting 2018

The Annual General Meeting 2018 is being held on Tuesday September 25, 2018 in the Oasmia Office at Vallongatan 1 in Uppsala.

The documentation for the Meeting is available in the PDF format below.

Documents

  • Minutes
    English September 25, 2018
  • Notice
    English
  • Power of Attorney
    English
  • The Board’s proposal for guidelines for remuneration to senior executive management
    English August
  • The Board’s proposal for issue authorization
    English August
  • The Board’s report on the Compensation Committee’s evaluation of remuneration to senior executives
    English September
  • Proposal for Nomination Committee
    English August
  • The Nomination Committee’s proposals and reasoned statement
    English August 24, 2018
  • Annual Report and Auditor’s Report 2017-05-01 – 2018-04-30
    English

Calendar

  • 26 Apr
    Annual Report 2020
  • 27 May
    Interim Report January – March 2021
  • 27 May
    Annual General Meeting 2021
All events
  • Corporate Governance
    • Governance reports
    • General Meeting
    • Management
    • Board of Directors
    • Nomination Committee
    • Remuneration
    • Auditor
    • Code of Conduct
    • Articles of Association
    • Documents
Oasmia logo
  • About Us
  • Our Science
  • Corporate Governance
  • Investors
  • Media
  • Contact

Oasmia Pharmaceutical AB develops, manufactures, markets and sells an improved generation of drugs within human and veterinary oncology. Product development aims to produce novel formulations of well-established cytostatic agents which show improved performance, an improved side-effect profile and a wider range of therapeutic areas compared with existing alternatives. Product development is based on the proprietary technology platform XR-17.

The Share

Follow the share
  • Personal data
  • Cookies

OAS-MA-P-001-SEP2020

Oasmia Pharmaceutical AB
Vallongatan 1, 752 28
Uppsala, Sweden
Tel +46 18 50 54 40
Fax +46 18 51 08 73
info@oasmia.com